Suppr超能文献

HFE基因H63D突变可预测中间型地中海贫血患者铁过载风险,与输血情况无关。

HFE mutation H63D predicts risk of iron over load in thalassemia intermedia irrespective of blood transfusions.

作者信息

Sharma Vineeta, Panigrahi Inusha, Dutta Pankhi, Tyagi Seema, Choudhry Ved Prakash, Saxena Renu

机构信息

Department of Hematology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi.

出版信息

Indian J Pathol Microbiol. 2007 Jan;50(1):82-5.

Abstract

Iron overload is a well-documented complication in thalassemia intermedia. Moreover, it is seen that the number of blood transfusions received does not correlate with the degree of overload. Since, HFE gene is associated with iron overload; the present study was conducted in an attempt to evaluate its role in thalassemia intermedia. The subjects were consecutive thalassemia intermedia cases attending the Hematology outpatient clinic. Controls were healthy hospital staff with negative family history of hemolytic anemia or liver disease. The molecular analysis for HFE mutations H63D and C282Y were done with primers described earlier. ELISA was used to measure serum ferritin. Sixty-three patients of thalassemia intermedia including 48 beta-homozygous/heterozygous thalassemia intermedia and 15 HbE-beta-thalassemia were studied. Six (12.5%) of the former and two (13.3%) of the latter were heterozygous for H63D; one of which, a 51-year old male also had clinical features of hemochromatosis. In healthy controls, prevalence of H63D heterozygosity was 7.5% (6/80). An interesting feature observed was that though the age and transfusions taken were similar in both groups, the serum ferritin greater than 500 ng/dl were observed in all patients (100%) with HFE mutation whereas it was seen in 12/42 (28.6 %) of patients without the mutation (p = 0.002). Thus, it is concluded that thalassemia intermedia patients with co-existent HFE mutation have a higher likelihood of developing iron overload and may require early iron chelation.

摘要

铁过载是中间型地中海贫血中一种有充分文献记载的并发症。此外,还发现接受输血的次数与过载程度并无关联。由于HFE基因与铁过载相关,因此开展本研究以评估其在中间型地中海贫血中的作用。研究对象为血液科门诊连续收治的中间型地中海贫血病例。对照组为无溶血性贫血或肝病家族史的健康医院工作人员。采用先前描述的引物对HFE突变H63D和C282Y进行分子分析。采用酶联免疫吸附测定法(ELISA)检测血清铁蛋白。对63例中间型地中海贫血患者进行了研究,其中包括48例β纯合子/杂合子中间型地中海贫血和15例HbE-β地中海贫血。前者中有6例(12.5%)、后者中有2例(13.3%)为H63D杂合子;其中1例51岁男性还具有血色素沉着症的临床特征。在健康对照组中,H63D杂合子的患病率为7.5%(6/80)。观察到一个有趣的现象是,尽管两组患者的年龄和输血次数相似,但所有携带HFE突变的患者(100%)血清铁蛋白均大于500 ng/dl,而未发生突变的患者中只有12/42(28.6%)出现这种情况(p = 0.002)。因此,得出结论,合并HFE突变的中间型地中海贫血患者发生铁过载的可能性更高,可能需要早期进行铁螯合治疗。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验